Symbio Herborn Group

Symbio Herborn Group is a German pharmaceutical and biotechnology group specializing in microbiome research and the development of probiotic-based therapies. The group comprises SymbioPharm, SymbioLabor, and SymbioVaccin, focusing on the production of live biotherapeutic products, specialized diagnostics, and autologous vaccines. Its flagship products, such as Symbioflor 1 and Symbioflor 2, are used to treat gastrointestinal and respiratory conditions by modulating the immune system through the gut-lung axis. In 2021, the group was acquired by the pharmaceutical company Pohl-Boskamp to strengthen its position in the microbiome market.